By Shilpa C Nangali

June 23, 2008 – Eli Lilly announced the results from olanzapine long-acting injection (LAI) clinical trials, which showed that the efficacy and safety profile of olanzapine LAI was generally consistent with that of Zyprexa with the exception of injection-related events. The study was presented at the first annual Schizophrenia International Research Society Conference in Venice, Italy. Regulatory reviews of olanzapine LAI applications are ongoing in the European Union, Canada, Australia and US.

Olanzapine LAI is an investigational formulation that combines olanzapine with a pamoate salt, resulting in an extended delivery of up to four weeks.

David McDonnell, M.D., clinical research physician at Lilly, said: “These studies offer insight into the potential of olanzapine LAI as a maintenance treatment for patients with schizophrenia who may have difficulty taking medication on a daily basis.”

Advertisements